{"denoms":[{"counts":[{"groupId":"BG000","value":"1619"},{"groupId":"BG001","value":"3399"},{"groupId":"BG002","value":"3312"},{"groupId":"BG003","value":"1389"},{"groupId":"BG004","value":"9719"}],"units":"Participants"}],"groups":[{"description":"Group 1 (Oncotype DX recurrence score =\\< 10): Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO","id":"BG000","title":"Arm A"},{"description":"Group 2 (Oncotype DX recurrence score 11-25): Patients receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO","id":"BG001","title":"Arm B"},{"description":"Group 2 (Oncotype DX recurrence score 11-25): Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO\n\nCombination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials","id":"BG002","title":"Arm C"},{"description":"Group 3 (Oncotype DX recurrence score \\>= 26): Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in Group 2 who are assigned to receive both types of treatment.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO\n\nCombination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials","id":"BG003","title":"Arm D"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"157"},{"groupId":"BG003","value":"79"},{"groupId":"BG004","value":"448"}],"title":"<=40 years"},{"measurements":[{"groupId":"BG000","value":"371"},{"groupId":"BG001","value":"985"},{"groupId":"BG002","value":"920"},{"groupId":"BG003","value":"330"},{"groupId":"BG004","value":"2606"}],"title":"41-50 years"},{"measurements":[{"groupId":"BG000","value":"563"},{"groupId":"BG001","value":"1235"},{"groupId":"BG002","value":"1206"},{"groupId":"BG003","value":"512"},{"groupId":"BG004","value":"3516"}],"title":"51-60 years"},{"measurements":[{"groupId":"BG000","value":"518"},{"groupId":"BG001","value":"868"},{"groupId":"BG002","value":"895"},{"groupId":"BG003","value":"395"},{"groupId":"BG004","value":"2676"}],"title":"61-70 years"},{"measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"134"},{"groupId":"BG003","value":"73"},{"groupId":"BG004","value":"473"}],"title":"71-75 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1619"},{"groupId":"BG001","value":"3399"},{"groupId":"BG002","value":"3312"},{"groupId":"BG003","value":"1389"},{"groupId":"BG004","value":"9719"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"39"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"140"},{"groupId":"BG002","value":"132"},{"groupId":"BG003","value":"51"},{"groupId":"BG004","value":"405"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"30"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"107"},{"groupId":"BG001","value":"236"},{"groupId":"BG002","value":"235"},{"groupId":"BG003","value":"115"},{"groupId":"BG004","value":"693"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"1361"},{"groupId":"BG001","value":"2883"},{"groupId":"BG002","value":"2783"},{"groupId":"BG003","value":"1162"},{"groupId":"BG004","value":"8189"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"10"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"117"},{"groupId":"BG002","value":"130"},{"groupId":"BG003","value":"55"},{"groupId":"BG004","value":"353"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"432"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"432"}],"title":"0-5"},{"measurements":[{"groupId":"BG000","value":"1187"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1187"}],"title":"6-10"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1214"},{"groupId":"BG002","value":"1159"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2373"}],"title":"11-15"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1368"},{"groupId":"BG002","value":"1344"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2712"}],"title":"16-20"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"817"},{"groupId":"BG002","value":"809"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1626"}],"title":"21-25"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"598"},{"groupId":"BG004","value":"598"}],"title":"26-30"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"315"},{"groupId":"BG004","value":"315"}],"title":"31-35"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"158"},{"groupId":"BG004","value":"158"}],"title":"36-40"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"202"},{"groupId":"BG004","value":"202"}],"title":"41-50"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"116"},{"groupId":"BG004","value":"116"}],"title":">50"}]}],"description":"The Oncotype DX assay is a 21-gene assay that predicts the likelihood of chemotherapy benefit and 10-year risk of distant recurrence to inform adjuvant treatment decisions in certain women with early-stage invasive breast cancer. Oncotype DX test results assign a Recurrence Score, and the Oncotype DX Recurrence Score is a continuous score, ranged between 0 and 100, that provides an individual estimate of the 10 year risk of distant recurrence and predicts the likelihood of benefit from chemotherapy. Higher score indicate higher risk of recurrence.","paramType":"COUNT_OF_PARTICIPANTS","title":"Recurrence score","unitOfMeasure":"Participants"}],"populationDescription":"All eligible patients who had on-study data and follow-up data were included in the analysis"}